This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Patrys Limited. Active years: 2017.
Company Filing History:
Years Active: 2017
Title: Lishanthi Udabage: Innovator in Antibody Development
Introduction
Lishanthi Udabage is a prominent inventor based in Rowville, Australia. She has made significant contributions to the field of biotechnology, particularly in the development of antibodies for therapeutic and diagnostic applications. Her innovative work has the potential to impact cancer treatment and improve patient outcomes.
Latest Patents
Lishanthi Udabage holds a patent for "LM-antibodies, functional fragments, LM-1 target antigen, and methods for making and using same." This invention provides LM-1 antibodies, functional fragments, modified and variant forms, nucleic acid, and other compositions. The antibodies and their functional fragments are designed to bind to the LM-1 antigen, which is crucial in the treatment and diagnosis of neoplasia, tumors, or cancer. One of the methods described in her patent includes treating metastasis of cancer by administering an effective amount of LM-1 antibodies to patients in need.
Career Highlights
Lishanthi Udabage is currently associated with Patrys Limited, a company focused on developing innovative antibody therapies. Her work at Patrys Limited showcases her commitment to advancing medical science and improving therapeutic options for patients.
Collaborations
Lishanthi collaborates with esteemed colleagues, including Stephanie Ute Brandlein and Arndt-Rene Kelter. These collaborations enhance the research and development efforts at Patrys Limited, fostering an environment of innovation and discovery.
Conclusion
Lishanthi Udabage is a trailblazer in the field of antibody development, with a focus on improving cancer treatment through her innovative patents. Her contributions to biotechnology are paving the way for new therapeutic approaches that could significantly benefit patients in need.